MatchBio provides a proprietary platform that creates custom synthetic receptors to boost the sensitivity, specificity, and binding affinity of CAR‑T cell therapies. By engineering modular receptor constructs compatible with existing manufacturing workflows, the company enables biopharma and cell‑therapy developers to enhance efficacy and reduce off‑target toxicities without redesigning their production processes.
Funding
$5.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current chimeric antigen receptor (CAR) T‑cell therapies often suffer from low sensitivity and limited specificity, leading to suboptimal tumor targeting, relapse, and a narrow range of treatable antigens.
Solution
MatchBio develops a proprietary platform of synthetic receptors that precisely match T‑cell receptors to their intended cancer targets. By engineering bespoke receptor constructs, the technology enhances binding affinity and functional activity of CAR‑T cells, aiming to reduce relapse rates and broaden the antigen landscape for therapy. The platform leverages deep immunology expertise from the University of Oxford to create receptors with improved specificity and reduced off‑target effects. These engineered receptors can be integrated into existing CAR‑T manufacturing pipelines, enabling developers to upgrade the performance of their cell therapies without redesigning the entire production process.
Target Audience
Primary customers are biopharmaceutical companies and cell‑therapy developers seeking to improve the efficacy and safety of their CAR‑T programs.
Features
- Custom-designed synthetic receptors that increase CAR‑T cell sensitivity and binding affinity
- Modular receptor architecture allowing rapid adaptation to new tumor antigens
- Enhanced specificity to minimize off‑target activity and associated toxicities
- Compatibility with standard CAR‑T manufacturing workflows and vector systems
- Data‑driven design informed by Oxford immunology research and structural modeling